查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2033152

轉錄組學市場規模、佔有率、趨勢和預測：按類型、技術、應用、最終用戶和地區分類，2026-2034年

Transcriptomics Market Size, Share, Trends and Forecast by Type, Technology, Application, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2025年全球轉錄組學市場規模為80億美元。展望未來，IMARC Group預測，該市場將在2026年至2034年間以5.08%的複合年成長率成長，到2034年達到127億美元。目前，北美是該市場的主要驅動力，佔37.7%的市場。該地區的需求得益於基因組學研究的持續進步、個人化醫療的日益普及、醫療研究的強勁投入以及主要市場參與者的存在。

轉錄組學是研究特定目標基因型在特定時間、特定條件下或特定細胞中啟動的核糖核酸（RNA）轉錄分佈的學科。它將基因組、蛋白質組和細胞表現型連結起來。轉錄組學涵蓋RNA的轉錄和表達水平、功能、定位、運輸和分解。在轉錄組學中，微陣列雜合反應、即時定量聚合酵素鏈鎖反應（Q-PCR）和次世代定序技術被用於鑑定基因轉錄結構。它還有助於研究人員表徵轉錄活性，重點關注相關目標基因和轉錄本的子集，並識別響應和對抗生物及非生物環境脅迫的基因和路徑。

轉錄組學的需求主要得益於次世代定序（NGS）技術的不斷進步，該技術顯著提高了基因表現分析的準確性和效率。此外，個人化醫療需求的日益成長也加速了轉錄組學在標靶治療生物標記識別方面的應用，從而促進了市場成長。同時，各國政府和私人機構對基因組研究投入的增加也推動了該領域的創新，並促進了市場擴張。例如，2025年1月，Truveta公司獲得了3.2億美元的資金籌措協議，用於建立全球最大的公開基因組資料庫之一，該資料庫包含1,000萬個基因組序列。 Regeneron Pharmaceuticals和Illumina等投資者也參與了該項目，旨在透過檢測遺傳傾向和疾病突變來提高藥物研發品質和患者照護水平。此外，產學合作正在加速產品開發和商業化進程，從而推動市場成長。

美國佔了82.90%的市場。該地區轉錄組學市場的成長得益於其強大的醫療保健基礎設施，為先進的研發提供了支援。此外，精密農業和植物性因組學的日益受到重視，也推動了轉錄組學在農業基因組學領域的應用，進而刺激了市場需求。同時，公共和私人機構對罕見疾病研究的投入不斷增加，也推動了對創新轉錄組學工具的需求。此外，單細胞轉錄組學在免疫學和腫瘤學領域的應用日益廣泛，也促進了市場成長。例如，Illumina與博德研究所合作，設計了一種採用CRISPR技術的新型基因定序盒，用於PerturbSeq篩檢。此類合作可望提升大規模基因定序，進而對疾病和治療方法建模產生深遠影響。此外，領先的生物製藥公司在該地區強大的市場地位也促進了轉錄組學技術的應用，並鞏固了市場佔有率。此外，政府大力推動生物技術和基因組學教育，透過培養技能人才來推動市場發展。

轉錄組學市場的發展趨勢：

轉錄組學、機器學習（ML）和人工智慧（AI）的整合

根據轉錄組學市場預測，機器學習 (ML) 和人工智慧 (AI) 的應用有望徹底改變該領域的數據分析方式。 AI 工具能夠有效解讀大規模資料集，並診斷基因表現中複雜的關聯和模式。 2024 年 2 月，多倫多大學的研究人員在《自然·方法》雜誌上發表了單細胞生成預訓練變壓器(scGPT) 模型。這是一種創新的 AI 模型，能夠有效預測特定基因操作的影響，並整合來自不同批次的數據，從而檢測通常無法追蹤的細胞類型。此外，該方法還有助於加深對疾病的理解、促進藥物發現和識別生物標記。機器學習模型還可以基於轉錄組數據預測疾病預後，從而顯著改善個人化醫療。隨著轉錄組數據複雜性的增加，機器學習 (ML) 和 AI 正迅速成為獲取有意義見解的不可或缺的工具，而這種融合是推動轉錄組學市場成長的主要趨勢。此外，人工智慧和機器學習在轉錄組學中的加速應用有望推動精準醫療和標靶治療的進步，從而能夠更準確、更快速地識別疾病機制和新的治療標靶。

單細胞轉錄組學的進展

單細胞轉錄組學的進步徹底改變了全球轉錄組學市場，使得在單一細胞層級進行基因表現的全面研究成為可能。隨著研究人員積極尋求闡明包括神經系統疾病和癌症在內的各種疾病中細胞異質性的方法，這一趨勢正迅速發展。癌症發生率的上升進一步推動了這一趨勢，因為單細胞轉錄組學對於理解腫瘤的複雜性以及開發個人化療法至關重要，從而促進了轉錄組學市場佔有率的擴大。產業報告顯示，2023年美國將新增超過190萬例癌症病例，預計死亡人數將達609,820人。此外，單細胞分析能夠精確闡明細胞行為，有助於發現創新生物標記和新的治療標靶。同時，技術的進步和成本的顯著降低正在迅速增加對單細胞轉錄組學的需求，推動臨床應用和學術研究領域的市場擴張。

在個人化醫療領域的擴展應用

隨著轉錄組學日益融入臨床研究，整個醫療保健領域的治療方案正在改變。轉錄組學市場分析表明，該研究領域在個人化醫療中正迅速獲得應用，因為了解個別基因表現有助於最佳化治療方法。這一趨勢主要受精準醫療日益成長的關注所驅動，尤其是在罕見疾病和癌症領域。根據業界報告顯示，功能性精準醫療可以為約55%對傳統治療方法無效的血液腫瘤（包括淋巴瘤和白血病）成年患者找到有效的治療方法。此外，轉錄組學透過識別患者特異性生物標記物，促進標靶治療的開發，並最大限度地降低藥物副作用的風險。因此，許多醫療機構和製藥公司正擴大採用轉錄組學技術來制定個人化治療策略。此外，隨著個人化醫療的普及，該領域預計將發揮關鍵作用，刺激全球需求，並為轉錄組學市場帶來光明前景。

在診斷和疾病分析中的應用日益廣泛

全球轉錄組學市場持續成長，這主要得益於轉錄組學在診斷和疾病分析中日益重要的作用，尤其是在理解腫瘤異質性和癌細胞群方面。轉錄組分析使研究人員能夠探索癌症的分子基礎，並獲得有關腫瘤進展的資訊。轉錄組技術正在擴展我們對腫瘤發生、腫瘤微環境和腫瘤免疫學的理解，並有助於發現新的癌症生物標記。此外，轉錄組策略被廣泛應用於生物醫學研究的各個領域，包括疾病診斷和分析。 RNA-Seq能夠廣泛識別轉錄起始位點，揭示可變啟動子的使用情況，並闡明新的剪接變化。 2024年，《國際生物技術雜誌》（J INTS BIO）宣布啟動一項由人工智慧主導的合作項目，以推動癌症治療。該合作計畫整合了包括轉錄組學在內的多組體學技術，旨在透過人工智慧開發個人化肺癌治療方法，提高藥物療效預測並降低毒性。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球轉錄組學市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 裝置
  • 消耗品
  • 軟體
  • 服務

第7章 市場區隔：依技術分類

  • 微陣列
  • 即時定量聚合酵素鏈鎖反應（Q-PCR）
  • 定序技術

第8章 市場區隔：依應用領域分類

  • 診斷和疾病分析
  • 藥物發現
  • 其他

第9章 市場區隔：依最終用戶分類

  • 學術研究機構
  • 製藥公司
  • 生技公司
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • BGI Group
    • Bio-Rad Laboratories Inc.
    • Biospyder Technologies Inc.
    • Illumina Inc.
    • Nanostring Technologies Inc.
    • Qiagen
    • Roche Holding AG
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
Product Code: SR112026A6585

The global transcriptomics market size was valued at USD 8.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 12.7 Billion by 2034, exhibiting a CAGR of 5.08% from 2026-2034. North America currently dominates, with 37.7% of the total transcriptomics market share. The demand in the region is driven by continuous advancements in genomic research, increasing adoption of personalized medicine, strong funding for healthcare research, and the presence of key market players.

Transcriptomics is the study of the allocation of ribonucleic acid (RNA) transcriptions initiated through the genotype of any determined object at an offered time, under certain conditions, or at a particular cell. It links the genome, the proteome, and the cellular phenotype. Transcriptomics encompasses RNA transcription and expression levels, functions, locations, trafficking, and degradation. Transcriptomics employs microarray hybridization, real-time quantitative polymerase chain reaction (Q-PCR), and next-generation sequences to identify the transcriptional architecture of a gene. It also assists researchers in characterizing transcriptional activity, focuses on a subset of relevant target genes and transcripts, and identifies genes and pathways that respond to and counteract biotic and abiotic environmental stresses.

The transcriptomics market demand is driven by the ongoing advancements in next-generation sequencing (NGS) technologies that have enhanced the accuracy and efficiency of gene expression analysis. In addition, the rising demand for personalized medicine is encouraging the use of transcriptomics to identify biomarkers for targeted therapies, aiding the market growth. Moreover, the increasing investments in genomic research by government and private entities are fueling innovation in the field, thus contributing to the market expansion. For instance, in January 2025, Truveta entered into a $320 million funding agreement for the building of what will be the largest public genomic database in the world at 10 million genomic sequences. This involves investors such as Regeneron Pharmaceuticals and Illumina and aims at surpassing the discovery of drugs and correspondent care of patients by detecting genetic tendencies or disease mutations. Furthermore, collaborations between academia and industry are fueling product development and commercialization, thus catalyzing the market growth.

The United States holds 82.90% of the market share. The transcriptomics market growth in this region is propelled by a robust healthcare infrastructure that supports advanced research and development (R&D). In line with this, the growing focus on precision agriculture and plant genomics is expanding transcriptomics applications in agrigenomics, fostering market demand. Concurrently, the rising public and private funding for rare disease research is driving the demand for innovative transcriptomic tools. Additionally, the increasing utilization of single-cell transcriptomics in immunology and oncology is fostering growth. For example, Illumina collaborated with the Broad Institute to design new gene sequencing kits employing CRISPR technology in PerturbSeq screening. Such a partnership is expected to enhance large-scale gene sequencing, which has a dramatic effect on disease and treatment modeling. Moreover, the strong presence of cutting-edge biopharmaceutical companies is boosting the adoption of transcriptomic technologies and strengthening the market share. Apart from this, increasing government initiatives promoting biotechnology and genomics education are cultivating a skilled workforce, thereby propelling the market forward.

TRANSCRIPTOMICS MARKET TRENDS:

Integration of Transcriptomics with ML and AI

According to the transcriptomics market forecast, the incorporation of machine learning (ML) and artificial intelligence (AI) is anticipated to revolutionize data analysis in this field. AI-powered tools can effectively interpret large datasets, diagnosing complicated correlations as well as patterns in gene expression. According to research article published in the journal Nature Methods in February 2024, researchers at the University of Toronto have developed a single-cell generative pre-trained transformer (scGPT), an innovative AI model that can efficiently predict the impacts of manipulating specific genes and can integrate different batches of data to detect otherwise untraceable cell types. Moreover, this approach bolsters disease comprehension, drug discovery, and biomarker identification. In addition, machine learning models can project disease outcomes based on transcriptomic data, significantly improving personalized medicine. As the intricacy of transcriptomic data elevates, ML and AI are rapidly becoming requisite for acquiring meaningful insights, positioning this integration as a key trend driving the transcriptomics market growth significantly. Furthermore, the accelerating adoption of AI and ML in transcriptomics is anticipated to boost advancements in precision medicine and targeted therapies, enabling more precise and faster identification of disease mechanisms and novel therapeutic targets.

Advancements in Single-Cell Transcriptomics

The development of single-cell transcriptomics has revolutionized the global transcriptomics market by facilitating the comprehensive study of gene expression at the individual cell level. This trend is rapidly gaining momentum as researchers are actively seeking ways to interpret cellular heterogeneity in various diseases such as neurological disorders and cancer. The growing prevalence of cancer further fuels this trend, as single-cell transcriptomics is requisite for understanding tumor complexity and developing personalized treatments, resultantly contributing to the expansion of transcriptomics market share. According to industry reports, more than 1.9 million new cancer cases were projected to be diagnosed in the U.S. in the year 2023, with 609,820 estimated deaths. Furthermore, single-cell analysis provides an accurate interpretation of cell behavior, resulting in the discovery of innovative biomarkers and new therapeutic targets. In addition, with increasing enhancements in technology and significant reductions in costs, the need for single-cell transcriptomics is substantially accelerating, bolstering the market expansion in both clinical applications and academic research activities.

Increasing Application in Personalized Medicine

The growing integration of transcriptomics in clinical research is transforming treatment protocols across healthcare sectors. The transcriptomics market analysis indicates that this field of study is rapidly being applied in personalized medicine, where comprehending individual gene expression profiles contributes to tailoring treatment methodologies. This trend is primarily propelled by the escalating interest in precision healthcare, especially in rare disorders and cancer. As per industry reports, functional precision medicine can effectively identify effective treatments for almost 55% of adult patients with blood cancers, including lymphoma and leukemia, who have not responded to conventional treatment methods. Moreover, by locating patient-specific biomarkers, transcriptomics facilitates the development of targeted therapies and minimizes the risk of adverse drug reactions. As a result, several healthcare providers as well as pharmaceutical firms are increasingly adopting transcriptomic techniques to formulate individualized treatment strategies. Furthermore, as personalized medicine becomes more prevalent, this field is anticipated to play a crucial role, spurring the demand globally and contributing to a positive transcriptomics market outlook.

Growing Use in Diagnostics and Disease Profiling

The global transcriptomics market is experiencing growth, significantly influenced by the increasing role of transcriptomics in diagnostics and disease profiling, especially in understanding tumor heterogeneity and cancer cell populations. Transcriptome analysis allows researchers to explore the molecular basis of cancer and provides information on tumor progression. Transcriptomic technologies are broadening knowledge about carcinogenesis, the tumor microenvironment, and immuno-oncology, as well as enabled the discovery of new cancer biomarkers. Furthermore, transcriptomic strategies are seeing wide usage in various fields of biomedical research, like disease diagnosis and profiling. RNA-Seq methods enable the extensive identification of transcriptional start sites, reveal alternative promoter utilization, and uncover new splicing changes. In 2024, J INTS BIO announced the launch of an AI-driven alliance to advance cancer therapy. This collaboration, which incorporated transcriptomics along with other multi-omics technologies, aimed to develop personalized lung cancer treatments through AI, enhancing drug efficacy prediction and reducing toxicity.

TRANSCRIPTOMICS INDUSTRY SEGMENTATION:

Analysis by Type:

  • Instruments
  • Consumables
  • Software
  • Services

Consumables represent the leading segment in the transcriptomics market with 43.8% shares, driven by their essential role in every phase of transcriptomic research. This category includes reagents, kits, probes, and microarrays, which are indispensable for sample preparation, gene expression analysis, and validation. Similarly, the flow of consumables has been triggered by high-throughput sequencing, real-time PCR, and many others all of which require many consumables. Moreover, as the rate of genetic and chronic diseases is on the rise, more research is being carried out which has promoted the recurrent purchase of consumables. The market has also contributed to the growth of the segment because of more efficient kits and reagents for single-cell transcriptomics technology. Besides this, the enhancement in opportunities for personalized medicine and biomarker identification also guarantees the steady growth of consumables' demand in the future.

Analysis by Technology:

  • Microarray
  • Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
  • Sequencing Technologies

Real-Time Quantitative Polymerase Chain Reaction (Q-PCR) is a leading technology segment in the transcriptomics market due to its unparalleled sensitivity, specificity, and quantification capabilities in gene expression analysis. As a fast and convenient method for confirming data produced by high-throughput sequencing and microarray analysis, Q-PCR is an essential tool of transcriptomics studies. The ability to sample different types as a norm besides the ability to analyse single cells up to tissues also puts the technology in a pole position. Furthermore, heel growth in clinical diagnostics particularly for cancer biomarkers, infective agents, and genetic disorders will augment market growth. Also, constant improvements in Q-PCR reagents, automation procedures, and high throughput platforms have pushed forward the efficiency and reliability of the technique so that it remains a favored technology in the transcriptomics arena.

Analysis by Application:

  • Diagnostics and Disease Profiling
  • Drug Discovery
  • Others

Drug discovery is a leading application segment, accounting for 33.8% of the market shares, driven by the growing need for precision medicine and innovative therapeutics. Transcriptomics is a key approach for the discovery of new drugs and targets, disease characterization, and drug response prediction based on the measurement of gene expression. These technologies are used in pharmaceutical and biotechnology firms as a tool to enhance discovery and bring new products to market faster and for less money. The availability of such sophisticated approaches as RNA sequencing and single-cell transcriptomics has improved the reliability of target definition and biomarker identification. In addition, chronic diseases are increasing, and personalized medicine gets more investment to maintain the constant usage of transcriptomics in drug discovery.

Analysis by End User:

  • Academic and Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Others

Academic and research institutes drive the transcriptomics market through extensive basic and applied research on gene expression. Their focus on exploring disease mechanisms, biomarker discovery, and innovations in technology underpins the growth of this critical end-user segment.

Transcriptomics is employed by pharmacological industries in drug development, clinical tests, and individualized medicine. As these companies use transcriptomic tools to discover cure points and improve the effectiveness of a drug, they are contributing immensely towards the growth of the market and technology.

Biotechnology companies employ transcriptomics for innovative solutions in genomics, agrigenomics, and personalized medicine. Their focus on developing new products and applications, such as RNA-based therapeutics, drives technological progress, significantly boosting the transcriptomics market trends.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America dominates the market with 37.7% of the market share due to its advanced healthcare infrastructure, strong focus on R&D, and robust funding from the public and private sectors. In line with this, the region benefits from the presence of leading pharmaceutical, biotechnology, and genomic companies driving innovation in transcriptomic technologies. For instance, Illumina's partnership with the Broad Institute of MIT and Harvard to scale up single-cell sequencing has the potential to greatly boost North America's advantage in genomic research and personalized medicine. This partnership seeks to make high-capacity single-cell experiments become a reality using Illumina's Fluent instrumentality. Moreover, the growing emphasis on precision medicine and the rising incidence of chronic and genetic disorders are significant drivers propelling market expansion. Besides this, the availability of advanced bioinformatics tools and expertise enhances the analysis of transcriptomic data. Furthermore, government-backed initiatives, including investments in genomic research and educational programs, create a favorable landscape for market growth. Apart from this, the region's strong network of academic and research institutions also fosters continuous advancements in transcriptomics, solidifying North America's leadership position in the global market.

KEY REGIONAL TAKEAWAYS:

UNITED STATES TRANSCRIPTOMICS MARKET ANALYSIS

The American Cancer Society reported that approximately 1.9 million new cancer cases were diagnosed in 2022, accompanied by 609,360 cancer-related deaths in the United States. The alarming prevalence demands advanced research tools, thereby fostering the growth of the transcriptomics market. As it gives insights into the gene expression pattern, transcriptomics plays a central role in the understanding of the molecular mechanisms related to cancer. This industry supports the identification of biomarkers to make a diagnosis of a disease earlier, track the progression of a disease, and create precise therapies. The need for accurate medicine is rising; therefore, this industry is indeed being contributed to by the federal government. In the National Cancer Institute, funding was USD 6.9 Billion in 2022, as per reports. Biopharmaceutical collaborations that are developing RNA-based cancer therapy are also driving this market. These all highlight the importance of transcriptomics in addressing the country's increasingly serious cancer burden.

EUROPE TRANSCRIPTOMICS MARKET ANALYSIS

EU4Health is described by the European Commission as the European Union's strategic response to the challenges thrown up by the COVID-19 pandemic to the healthcare systems, medical staff, and patients of Europe. It encompasses a wide program that aims to move beyond crisis management into building a stronger, healthier, and more resilient Health Union. As the biggest health initiative ever undertaken by the EU, EU4Health will dedicate more than Euro 5 Billion (USD 5.1 Billion) over seven years (2021-2027) to improving healthcare outcomes in the region. EU4Health's efforts to enhance healthcare infrastructure, coupled with promoting innovative research, will provide major growth opportunities in the transcriptomics market in Europe. Through funding advanced technologies and encouraging multi-state collaborative research, EU4Health is paving the way for the use of transcriptomic tools to understand and diagnose diseases more effectively and through personalized medicine. Such initiatives can be best aimed at combating complicated diseases such as cancer, rare genetic diseases, and chronic illnesses while ensuring Europe is a leader in innovative healthcare products.

ASIA PACIFIC TRANSCRIPTOMICS MARKET ANALYSIS

According to NCBI, cancer-related medical costs in Asia will be increased dramatically in the future. The projected increase is expected to be around JPY 686.4-1,104.2 Billion (USD 6.2-10.0 Billion) by FY 2050. This necessitates the high priority of this disease area for sustainable medical financing in the region. The increased costs underscore the need for innovative research tools, such as transcriptomics, to improve the efficacy of cancer diagnostics, treatment strategies, and drug development. The Asia-Pacific region is witnessing growth in healthcare infrastructure and government initiatives to address the growing burden of cancer. The high population density and increasing prevalence of chronic diseases in the region make transcriptomics a critical tool in advancing precision medicine and improving patient outcomes. China, India, and Japan are the driving countries for this movement, increasing investment in biotechnology research and linking academia with the industry. In that respect, Asia-Pacific represents a huge market for transcriptomics advancement.

LATIN AMERICA TRANSCRIPTOMICS MARKET ANALYSIS

The growing prevalence of cancer in Latin America, particularly in middle-income mixed-economy countries like Brazil, is a significant factor driving the region's transcriptomics market. In the last 15 years, Brazil has experienced a steady annual increase in cancer cases, from 472,050 in 2005 to 489,270 in 2010, 576,000 in 2015, and reaching 625,000 cases per year from 2020 to 2022, according to the American Society of Clinical Oncology (ASCO). This increasing incidence calls for more advanced molecular research tools, including transcriptomics, to enhance the diagnostic and treatment planning of cancer and drug development. Since the region's healthcare systems have put more focus on the growing burden of cancer, the adoption of transcriptomics in uncovering patterns of gene expression and promoting personalized medicine approaches is becoming important. Investments in research infrastructure and discussions with local institutions and global biotech firms are also in place to speed up the adoption of transcriptomics technologies. The demand for targeted therapies and better health outcomes places Latin America at the epicenter of emerging markets for transcriptomics innovation.

MIDDLE EAST AND AFRICA TRANSCRIPTOMICS MARKET ANALYSIS

The rapid advancement in health research happening in the UAE is a highly driving factor towards the growth in the transcriptomics market in the Middle East and Africa region. According to the Ministry of Health and Prevention report, the country has been witnessing a growth rate in its health research sector thrice as high compared to the global average; this even reached an astonishing 25.2% increase in research outputs from 2017 to 2022. This signifies an important strategic focus by the UAE on creating innovation and excellence in healthcare and biomedical sciences. The UAE has also emerged as a major GCC country collaborator in health research. About 80% of the health research published in the UAE is conducted in collaboration with international institutions, which reflects its commitment to global scientific cooperation. According to MoHAP, this collaborative environment is bolstering advancements in molecular and genomic research, including transcriptomics. Supported by strong government initiatives and partnerships, these efforts pave the way for better health solutions and innovative technology adoption in the region.

COMPETITIVE LANDSCAPE:

The transcriptomics market is highly competitive, driven by continuous innovation and strategic efforts from leading industry players. Companies are focusing on developing advanced technologies, such as single-cell transcriptomics and high-throughput RNA sequencing, to enhance data accuracy and efficiency. Strategic collaborations between pharmaceutical firms, biotechnology companies, and academic institutions are becoming increasingly common, fostering innovation and accelerating product development. Industry players are making significant investments in research and development to launch innovative consumables and software solutions designed for personalized medicine and drug discovery. Mergers, acquisitions, and strategic partnerships are key trends, allowing companies to broaden their portfolios and extend their global presence. Moreover, the integration of artificial intelligence and machine learning into transcriptomics is gaining momentum, further fueling market expansion.

The report provides a comprehensive analysis of the competitive landscape in the transcriptomics market with detailed profiles of all major companies, including:

  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • BGI Group
  • Bio-Rad Laboratories Inc.
  • Biospyder Technologies Inc.
  • Illumina Inc.
  • Nanostring Technologies Inc.
  • Qiagen
  • Roche Holding AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Transcriptomics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Instruments
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Consumables
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Software
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Services
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Microarray
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Sequencing Technologies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Diagnostics and Disease Profiling
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Discovery
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Academic and Research Institutes
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Pharmaceutical Companies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Biotechnology Companies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agilent Technologies Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Becton Dickinson and Company
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 BGI Group
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Biospyder Technologies Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Illumina Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Nanostring Technologies Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Qiagen
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Roche Holding AG
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
    • 15.3.10 Takara Bio Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 Thermo Fisher Scientific Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Transcriptomics Market: Major Drivers and Challenges
  • Figure 2: Global: Transcriptomics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Transcriptomics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Transcriptomics Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Transcriptomics Market: Breakup by Technology (in %), 2025
  • Figure 6: Global: Transcriptomics Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Transcriptomics Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Transcriptomics Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Transcriptomics (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Transcriptomics (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Transcriptomics (Consumables) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Transcriptomics (Consumables) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Transcriptomics (Software) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Transcriptomics (Software) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Transcriptomics (Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Transcriptomics (Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Transcriptomics (Microarray) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Transcriptomics (Microarray) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Transcriptomics (Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Transcriptomics (Real-Time Quantitative Polymerase Chain Reaction (Q-PCR)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Transcriptomics (Sequencing Technologies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Transcriptomics (Sequencing Technologies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Transcriptomics (Diagnostics and Disease Profiling) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Transcriptomics (Diagnostics and Disease Profiling) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Transcriptomics (Drug Discovery) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Transcriptomics (Drug Discovery) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Transcriptomics (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Transcriptomics (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Transcriptomics (Academic and Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Transcriptomics (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Transcriptomics (Pharmaceutical Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Transcriptomics (Pharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Transcriptomics (Biotechnology Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Transcriptomics (Biotechnology Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Transcriptomics (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Transcriptomics (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Transcriptomics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Transcriptomics Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Transcriptomics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Transcriptomics Industry: SWOT Analysis
  • Figure 87: Global: Transcriptomics Industry: Value Chain Analysis
  • Figure 88: Global: Transcriptomics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Transcriptomics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Transcriptomics Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Transcriptomics Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Transcriptomics Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Transcriptomics Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Transcriptomics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Transcriptomics Market: Competitive Structure
  • Table 8: Global: Transcriptomics Market: Key Players